Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.M609101200 on December 27, 2006

J. Biol. Chem., Vol. 282, Issue 10, 6965-6975, March 9, 2007
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
282/10/6965    most recent
M609101200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Williams, L. M.
Right arrow Articles by Foxwell, B. M. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Williams, L. M.
Right arrow Articles by Foxwell, B. M. J.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Expression of Constitutively Active STAT3 Can Replicate the Cytokine-suppressive Activity of Interleukin-10 in Human Primary Macrophages*

Lynn M. Williams1, Usha Sarma, Kate Willets, Tim Smallie, Fionula Brennan, and Brian M. J. Foxwell

From the Kennedy Institute of Rheumatology Division, Imperial College London, ARC Building, 1 Aspenlea Road, London W6 8LH, United Kingdom

Received for publication, September 26, 2006 , and in revised form, December 1, 2006.


   ABSTRACT
TOP
 ABSTRACT
INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
There is general agreement that signal transducer and activation of transcription 3 (STAT3) is required to mediate the anti-inflammatory activities of interleukin (IL)-10. However, STAT3 is activated by multiple factors that do not share the anti-inflammatory activity of IL-10. The question remains whether STAT3 is sufficient for the anti-inflammatory effects or whether there are other signals required, as had been suggested previously. We set out to map the human IL-10 receptor and to identify the key elements involved in transducing the cytokine-suppressive effects of IL-10. We were able to show an absolute requirement for both of the tyrosine residues found within the YXXQ-STAT3-docking site within the IL-10 receptor 1 and that no other signals appeared to be required. We used a constitutively active STAT3 to determine whether expression of this factor could suppress lipopolysaccharide-induced tumor necrosis factor and IL-6 production. Our data show that STAT3 activity can suppress both IL-6 and tumor necrosis factor production in lipopolysaccharide-stimulated macrophages. However, in synovial fibroblasts, STAT3 did not suppress IL-6 production, suggesting that the cellular environment plays an important role in dictating whether STAT3 drives a pro- or anti-inflammatory response.


   INTRODUCTION
TOP
 ABSTRACT
 INTRODUCTION
EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Inflammation is a key aspect of the host defense against infection and injury. However, if prolonged the inflammatory response can have deleterious effects on the host as seen in chronic auto-inflammatory conditions. Therefore, multiple mechanisms have evolved to regulate and curtail inflammatory responses. One of the most potent is interleukin (IL)2-10. The importance of IL-10 to immune homeostasis is clearly demonstrated in IL-10-deficient mice that spontaneously develop inflammatory bowel disease (1). The potency of the anti-inflammatory effects of IL-10 has been demonstrated in animal models of inflammation such as sepsis (2), collagen-induced arthritis (3), insulitis (4), and in some models of experimental autoimmune encephalitis (5, 6). In a clinical setting, encouraging data have emerged from phase II trials of systemically administrated IL-10 in the treatment of psoriatic skin lesions (7), although similar data from trials in Crohn disease and rheumatoid arthritis produced only a mild amelioration of disease activity, although treatment was limited by toxicity (8, 9).

IL-10 has multiple effects on the immune response (10), the principal of which is inhibition of macrophage activation. IL-10 exerts its negative regulation on macrophage activation by inhibiting key activation processes, such as antigen presentation, by down-regulating major histocompatibility complex class II and co-stimulatory molecules CD80/86 (11–13), inhibiting the expression of cyclooxygenase 2 (COX2), and enhancing the release of anti-inflammatory factors such as soluble TNF receptors (R) and IL-1 receptor antagonist (14). One of the most potent anti-inflammatory effects of IL-10 is the suppression of pro-inflammatory cytokines and chemokines and in particular the key therapeutic target TNF.

However, despite extensive research, the intracellular molecular mechanism by which IL-10 inhibits TNF expression or mediates its other anti-inflammatory effects remains unclear. The IL-10R (15–17) is composed of two chain, IL-10R1 and CRF4/IL-10R2 (18, 19), that are members of the class II/interferon (IFN) subgroup of cytokine receptors. IL-10 activates Jak-1 and Tyk-2 (20) resulting in the activation of signal activator of transcription (STAT) 3; in addition the activation of STAT1 and STAT5 has also been reported (21–24). The numerous studies investigating how IL-10 suppresses cytokine expression have proved to be both controversial and often contradictory with a variety of transcriptionally, post-transcriptionally, and translationally mediated mechanisms being described (25–30). It is also unclear whether the effects of IL-10 on cytokine expression are direct or require de novo gene expression (31, 32). For instance, the induction of Bcl-3 expression has been proposed to be required, as murine macrophages deficient in this gene show no suppression of TNF production in response to IL-10 (33). Alternatively, it has been suggested that IL-10 simply antagonizes LPS-induced stabilization of mRNA as in the case of the chemokine KC (34). More recent data would suggest that the mechanism is indeed indirect as studies by Murray (35) have shown that IL-10 targets inflammatory gene transcription via the induction of intermediate gene(s) products.

Despite the general diversity of mechanisms advocated for the anti-inflammatory activity of IL-10, there appears to be general agreement from knock-out mice and the use of dominant negative constructs that the Jak1/STAT3 axis is essential for this anti-inflammatory, as both Jak1 and STAT3 are utilized by many other cytokines that do not evoke the anti-inflammatory activity of IL-10. A previous study by Riley et al. (38) using an IFN {gamma}-IL-10 receptor chimera introduced into the murine cell line RAW264.7 suggested that an additional signal to STAT3, provided by a serine-rich region near the C terminus, was required to block TNF production. This view is supported by the observation that expression of a constitutively active STAT3 could not inhibit TNF production in murine dendritic cells (39). However, what precise role this serine-rich region played has never been elucidated or confirmed. Neither have the possible confounding effects of using an interferon/IL-10 hybrid receptor been examined.

In this study we have investigated which regions of the cytoplasmic domain of the human IL-10R are required for the regulation of TNF and IL-6 production in primary human macrophages and whether STAT3 is sufficient to mediate IL-10 function in this context. We could find no role for the C-terminal serine-rich region (38), and only deletion of both of the tyrosines that provide the STAT3-docking sites could ablate IL-10 signaling. To demonstrate that STAT3 is indeed both necessary and sufficient to mediate the anti-inflammatory response, we introduced a constitutively active form of STAT3 (STAT3C) into macrophages. STAT3C was able to mimic the inhibitory activity of IL-10, inhibiting LPS-induced TNF and IL-6 production but sparing IL-10 production and inducing Bcl-3 production. To our knowledge, these data are the first to show that STAT3 is the only signal required to convey the major anti-inflammatory activity of IL-10 within human myeloid cells.


   EXPERIMENTAL PROCEDURES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
RESULTS
 DISCUSSION
 REFERENCES
 
Reagents—IL-10 was a kind gift from Schering Plough; macrophage colony-stimulating factor was a kind gift from Wyeth (Boston); Salmonella typhi LPS was purchased from Alexis (Dorset, UK); anti-HLA DR-CyChrom and Ig-conjugated CyChrom were purchased from BD Biosciences. TNF, IL-6, and IL-10 ELISA reagents were purchased from BD Biosciences.

Cells—Monocytes were isolated by centrifugal elutriation as described previously (40). Macrophages were derived from monocytes by culturing the cells with macrophage colony-stimulating factor at 100 ng/ml (41). RA mononuclear cells and synovial fibroblasts were isolated from patients undergoing joint replacement surgery and were isolated as described previously (41).

Adenoviral Vectors and Viral Infections—The murine/human IL-10R1 chimeric adenoviral vectors were constructed from full-length murine and human IL-10R1 cDNAs using PCR. Primers used were as follows: m/hIL-10RI, 5'Mur 5'-GCTAGCATGTTGTCGCGTTTGCTCCCA-3' and 3'MurSSpI 5'-GCTAGCGTCGACAAGCTTACAGTGAAATATTGCTCCGTCGT-3'; 5'HumSSpI 5'-CACCAGGCAATATTTCACCGT-3' and 3'Hum 5'-AAGCTTTCACTCACTTGACTGCAGGCTAGA-3'; 3'HumFLAG 5'-AAGCTTTCACTTGTCATCGTCGTCCTTGTAGTCCTCACTTGACTGCAGCTAGA-3' and 3'flm 5'-GGCAAGCTTTCATTCTTCTACCTGCAGGCTGG-3'. The 3' modifications used are as follows: 3'4SA 5'-AAGCTTTCACTCACTTGACTGCAGAGCTGCGATGAGGGGCAGGGTGACCAGGTCTGCGTTAAATGCGCCCAG-3'; 3'1738Del 5'-GGCAAGCTTTCAGCCCAGGAGACCACCTGGGGCTGC-3'; and 5'-TATAAGCTTTCACTTGTCATCGTCGTCCTTGTAGTCACATCTGGTCTGCCTCAGGTA-3'. The site-directed mutagenesis primers are as follows: 5'Tyr-446 5'-GCTGCTGTGGCATTCCAGGGTTTCCTGAGGCAGACCAGATGTGCT-3' and 3'-Tyr-446 5'-CGACGACACCGTAAGGTCCCAAAGGACTCCGTCTGGTCTACACGA-3'; 5'-Tyr-496 5'-CCACCAGCCCTGGCCAAGGGCTTCTTGAAACAGGATCCTCTAGAA-3' and 3'-Tyr-496 5'-GGTGGTTCGGGACCGGTTCCCGAAGAACTTTGTCCTAGGAGATCTT-3'. The full-length m/hIL-10RI chimeric construct was generated through the introduction of an SspI restriction enzyme site in the membrane-proximal sequence of the 5' section of the mIL-10R1 and the 3' section of the hIL-10R1 using primers 5'Mur and 3'HumSspI. The PCR fragments were cloned into an intermediate blunt-end cloning vector, using the pCR Blunt II vector and TOPO cloning kit (Invitrogen). The 5' primer contained an NheI, and all 3' primers contained a HindIII site to allow directional subcloning of the PCR fragment. Deletion mutants were generated from full-length m/h IL-10RI using PCR with the appropriate primers. Site-directed mutagenesis was performed on full-length m/h IL-10RI using QuickChange site-directed mutagenesis kit (Stratagene, La Jolla, CA) according to manufacturer's instructions. The m/hIL10RI Tyr-446/496 was generated through two rounds of site-directed mutagenesis, the first with the Tyr-446 and the second with the Tyr 496 primers. All standard PCRs were carried out at 4 min at 92 °C and then 35 cycles for 30 s at 92 °C, 30 s at 60 °C, 2 min at 72 °C per cycle, and then 10 min at 72 °C. Following transformation and amplification of the DNA in Escherichia coli, each clone was sequenced. p4xM67-tk-luci was generated as described previously (42). A 175-bp fragment containing the 4xM67 consensus sequence was excised using SalI/XhoI. The fragment was blunted using the Stratagene (La Jolla, CA) polishing kit as per the manufacturer's instructions and cloned into pGL3, which had been opened using XhoI and phosphatase-treated shrimp alkaline (Promega, Madison, WI). Orientation was confirmed using restriction enzyme digestion. The 4xM67-STAT3 luciferase fragment from p4XM67-pGL-3 was excised using KpnI/SalI and cloned into pAdtrack. The constitutively activate STAT3C viral construct was a gift from Dr. Michitaka Ozaki (National Research Institute for Child Health and Development, Setagaya, Japan (43)). The NF-{kappa}B reporter adenovirus was provided by Dr. P. B. McCray, Jr. (University of Iowa, Iowa City) and is a modification of the pNF-{kappa}B reporter vector (Clontech) (44).

The adenoviral vectors were generated through homologous recombination in BJ bacterial cells, purified, and concentrated, based on the method devised by He et al. (7) and as described previously (41). Macrophages were routinely infected with virus at the stated multiplicity of infection (m.o.i.) for 1 h in serum-free medium. Cells were washed and recultured in growth medium with 5% (v/v) fetal calf serum for 24 h.

Immunoprecipitation and Western Blot Analysis—Stimulated cells were lysed in 1% Triton X-100 lysis buffer (20 mM Tris, pH 7.6, 150 mM NaCl, 1 mM EDTA, 1 mM Na2VO4, 0.5 mM NaF, and protease inhibitor mixture (Sigma)) for 10 min. Lysates were clarified by centrifugation and for immunoprecipitation purposes were pre-cleared with 20 µl of protein G-Sepharose (Amersham Biosciences). STAT3C was immunoprecipitated with 5 µg of anti-FLAG M2 (Sigma) for 2 h followed by the addition of 20 µl of protein G-Sepharose. Immune complexes were washed three times in 1 ml of Triton lysis buffer. Samples were separated by electrophoresis through 10% SDS-polyacrylamide gels and transferred to polyvinylidene difluoride membranes (Millipore) that were blocked for 1 h with blocking buffer (5% w/v fat-free milk, 0.1% (v/v) Tween 20 in PBS) followed by 1 h of incubation with the antibodies, diluted 1:1000 in blocking buffer. Antibodies used were anti-Tyr-705 phospho-STAT3 and anti-STAT3 (New England Biolabs), anti-beta-tubulin (Sigma), anti-FLAG M2 (Sigma), anti-HA (Covance, CA), anti-Bcl-3, and anti-SOCS3 (Santa Cruz Biotechnology). Horseradish peroxidase-conjugated anti-mouse IgG or anti-rabbit IgG (Amersham Biosciences) was used as secondary antibodies at a dilution of 1:2000. Bound antibody was detected using the enhanced chemiluminescence kit (Amersham Biosciences) and visualized using Hyperfilm MP (Amersham Biosciences).

Quantitation of Gene Expression by Real Time TaqMan RT-PCR—RNA was isolated using a Qiagen RNA blood isolation kit (Qiagen. Ltd., Crawley, UK). TaqMan RT-PCR core reagent kit, TNF, IL-6, and glyceraldehyde-3-phosphate dehydrogenase primer/probe mixtures were purchased from PE Biosystems (Warrington, Cheshire, UK). An ABI PRISM 7700 detector sequence was programmed for the initial step of 2 min at 50 °C and 10 min at 95 °C followed by 40 cycles of 15 s at 95 °C and 1 min at 60 °C. Relative quantitation of gene expression was determined using the comparative CT method. All calculations followed procedures outlined in ABI PRISM 7700 sequence detective system bulletin 2.

Luciferase Assays—After stimulation, cells were washed once in PBS and lysed with 100 µl of CAT lysis buffer (0.65% (v/v) Nonidet P-40, 10 mM Tris-HCl, pH 8, 0.1 mM EDTA, pH 8, 150 mM NaCl). 50 µl of cell lysate was transferred into the well of a luminometer cuvette strip containing 120 µl of luciferase assay buffer (1% Triton X-100, 25 mM Tris, pH 7.8, 8 mM MgCl2, 15% glycerol, 1 mM EDTA, 0.5 mM ATP, 1 mM dithiothreitol). Luciferase activity was measured with a Labsystem luminometer by dispensing 30 µl of luciferin (Bright-Glo luciferase assay system; Promega) per assay point. Cell lysates were assayed for protein concentration by the Bradford assay, and luciferase activity was adjusted accordingly.

FACS Analysis—Macrophages were seeded at 106 cells/well and infected at an m.o.i. of 100 with Ad GFP, Ad m/h-IL-10RI chimera, or the Ad IL-10RI mutants and left to express overnight. The cells were detached with Accutase (PAA Laboratories, Yeovil, UK) and were blocked in FACS wash buffer (PBS, 2% (v/v) fetal calf serum, 0.025% (v/v) NaN3, 2 mM EDTA). Cell surface expression of adenovirally expressed m/hIL-10R1 receptors was assessed using a monoclonal rat anti-mouse IL-10R1 antibody (clone 1B1.3a) kindly donated by Dr. Kevin Moore, DNAX Inc., Palo Alto, CA. 1B1.3a was biotinylated using the EZ-Link Sulfo-NHS-LC biotinylation kit (Pierce) following the manufacturer's instructions. Cells were incubated with either 1B1.3a or biotinylated isotype control (Serotech, Kidlington, Oxon, UK) followed by incubation with streptavidin Per-CP (Pharmingen). Cells were analyzed on a BD Biosciences LSR FACScan.


   RESULTS
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
DISCUSSION
 REFERENCES
 
Rationale and Design of Chimeric Murine/Human IL-10R1 Adenoviral Constructs—This study was performed in primary human macrophages to ensure the greatest relevance to human physiology as possible. To identify functionally critical amino acid residues within the intracellular domain of the IL-10RI, we generated a number of chimeric receptors. These consisted of the murine IL-10RI extracellular domains that were fused with the human IL-10RI chain in an 8-amino acid sequence (QYFTVTN), just proximal of the transmembrane region (n = amino acid residue 238 of the murine receptor), which is identical between species (Fig. 1a). The resulting chimeric receptor should be sensitive to stimulation by both murine and human IL-10, whereas the endogenously expressed human IL-10R is only sensitive to human IL-10. Therefore, by using murine IL-10 to stimulate cells, any effect of the endogenous human IL-10R would be avoided, allowing us to specifically analyze the effects of any mutations we care to introduce. Using this construct as a backbone, a series of mutations and deletions were generated to map the cytoplasmic domain of the human receptor (Fig. 1a). In particular, the (only) two tyrosine residues within a YXXQ motif at 446 and 496 were mutated to phenylalanine (Y446F, Y496F, and Y446F/Y496F). These tyrosines correspond to Tyr-427 and Tyr-477 in the murine receptor which have been shown previously to serve as docking sites for the recruitment of STAT3 (24, 45). We also wanted to investigate whether the homologous four serine residues identified by Riley et al. (38) near the C terminus of the murine receptor were also important. A truncation was made to remove these from the human IL-10R. In addition, a serine -> alanine mutant of these homologous four serine residues in the human IL-10R1 was also constructed truncated after amino acid 579 (see "Experimental Procedures"). To achieve efficient expression of the murine/human IL-10R constructs in human macrophages, they were inserted into adenoviral vectors. As shown in Fig. 1b, using an anti-murine IL-10R1-specific antibody, we were able to detect expression of all chimeric receptors in the human macrophages.

IL-10-induced STAT3 Phosphorylation and SOCS3 Induction in m/h IL-10RI Chimera-infected Cells—To function as a signaling receptor, the IL-10R1 has to associate with the ubiquitously expressed IL-10R2. Because it was not possible to assess the assembly of such a complex with the m/h chimeras, we used the activation of signaling activity as an indicator of chimera function. Tyrosine phosphorylation of STAT3 is by far the strongest immediate effect of IL-10 signaling, and this was therefore used to test for m/h IL-10R function. In addition, a second readout of IL-10 signaling, the induction of SOCS3 expression, was also assayed. Both the phosphorylation of STAT3 and the induction of SOCS3 were assayed by Western blot. Macrophages infected with a control virus (Ad GFP) (as expected) did not respond to murine IL-10 but did respond to human IL-10 as judged by phosphorylation of STAT3 or the induction of SOCS3 gene expression (Fig. 2, a and b). In contrast, infection with the construct containing the full-length m/h chimera resulted in cells becoming responsive to murine IL-10 as judged by the phosphorylation of STAT3 and SOCS3 expression (Fig. 2, a and b). Constructs containing single mutations at Tyr-446 or Tyr-496 and the serine-rich region were also still responsive to murine IL-10 as shown by the same criteria. However, the double mutation of both tyrosines Y446F/Y496F and the complete cytoplasmic deletion abolished STAT3 (Tyr-705) phosphorylation and the induction of SOCS3 expression (Fig. 2, a and b).


Figure 1
View larger version (29K):
[in this window]
[in a new window]

  		FIGURE 1.
Surface expression of murine/human IL-10 RI adenoviral constructs in human macrophages. a, schematic diagram of m/h IL-10 receptor mutants. Full-length murine extracellular and human intracellular IL-10R1, tyrosine at human position 446 is mutated to Phe (Y446F); tyrosine at human position 496 is mutated to Phe (Y496F); and both tyrosines at position Y446F/Y496F are mutated to Phe and C-terminal serine-rich deletion (Ser-RD) at 1738 bp. b–g, 106 macrophages were infected at an m.o.i. of 100 with Ad GFP (hatched arrow), Ad m/h-IL-10RI chimera (solid arrow)(b and g); or the Ad IL-10R1 mutants (c–g) and left to express overnight. Cell surface expression of adenovirally expressed m/hIL-10RI receptors was assessed using a biotinylated-monoclonal rat anti-mouse IL-10RI antibody, followed by incubation with streptavidin Per-CP and analyzed on an LSR FACScan (BD Biosciences). b, full-length murine/human IL-10RI; c, Y446F mutant; d, Y496F mutant; e, double Tyr mutant 446/496; f, C-terminal serine-rich region deletion (Ser-RD); g, full-length murine/human IL-10RI stained with an isotype control.

 
Tyr-446/496 Are Required to Mediate IL-10 Inhibition of LPS-induced TNF and IL-6 Production—The data presented in this study show that there is a redundancy between the two cytoplasmic tyrosine residues in their ability to induce STAT3 phosphorylation and a downstream effector gene SOCS3. It was also clear from the expression data in Fig. 1 that failure to induce STAT3/SOSC3 signaling is not related to a failure of the constructs to express. Next the ability of the various constructs to mediate the anti-inflammatory activity of IL-10 was evaluated by assessing the inhibition of LPS-induced TNF and IL-6 production. As shown in Fig. 2, in uninfected cells or those infected with Ad GFP control virus, LPS-induced TNF (d) and IL-6 (e) production was effectively inhibited by addition of human IL-10 but not by murine IL-10. Expression of m/h IL-10R1 rendered the cells sensitive to murine IL-10 with the expression of both TNF and IL-6 being inhibited. In parallel with the induction of STAT3/SOCS3 signaling (Fig. 2, a and b), both the single Y446F and Y496F mutants and the serine-rich domain mutant were also able to mediate the inhibitory activity of murine IL-10. Only the Y446F/Y496F and the cytoplasmic deletion failed to support a murine IL-10 response. In summary, these data would indicate that the ability to induce STAT3 activity strongly correlates with IL-10 anti-inflammatory activity. However, in contrast with the study of Riley et al. (38), we found no requirement for the conserved serine residues.

Generation of a Constitutively Active STAT3 (STAT3C)—The data support the view that STAT3 is necessary to mediate the anti-inflammatory effects of IL-10. The data also indicate that it is unlikely that another signal generated by the IL-10R (other than from the tyrosine residues) is required in addition to STAT3. There are two caveats to this supposition. There may be other signals that emanate from tyrosines 446 and 496 other than STAT3 and/or there are sequences in the membrane proximal region, in addition to the Box1 site for Jak1 association, that mediate the anti-inflammatory effect. Deletions of this region were not made because of the potential to interfere with Jak1 binding and activation. Therefore, to test whether STAT3 alone was necessary and sufficient and to determine whether either of the above caveats may be true, a constitutively active STAT3 (STAT3C) (46) was cloned into an adenoviral vector for expression in macrophages. This mutant is constitutively active as a result of substituting the cysteine residues for C661A and C663N, allowing STAT3 dimerization and activation. More recent studies have shown that tyrosine phosphorylation of STAT3C is critical to achieve maximal DNA binding affinity, which results in a slower off-rate and protects STAT3C from inactivation from phosphatases (47, 48). Fig. 3a shows high levels of expression of STAT3C in macrophages infected with increasing m.o.i., as detected by Western blotting of the FLAG-tagged STAT3C. To confirm that the STAT3C was constitutively active, cells were co-infected with a second virus encoding a STAT3-response element (M67 SIE) driving the expression of the luciferase gene. The STAT3-luciferase reporter construct responded to IL-10 and less so to IL-6, another STAT3-activating cytokine (Fig. 3b). This is in keeping with our previous observations that IL-10 induces a more sustained level of STAT3 phosphorylation than IL-6 (40). Expression of the STAT3C adenovirus produced a powerful dose-dependent activation of the STAT3 reporter gene with the maximal response occurring at an m.o.i. of 100 of the Ad STAT3C (Fig. 3c). The strength of the stimulus over that of IL-10 could be expected from the high level of overexpression of the STAT3C molecule. We observed very low level constitutive phosphorylation of STAT3C, which could be substantially enhanced by addition of either IL-10 (not shown) or LPS (Fig. 3, d and e). This was detectable within 60 min of post-LPS stimulation. To confirm the functional activity of STAT3C, we were also able to demonstrate that the expression of the molecule alone was able to induce the expression of the IL-10 inducible gene SOCS3 (Fig. 3f).


Figure 2
View larger version (37K):
[in this window]
[in a new window]

  		FIGURE 2.
IL-10-induced STAT3 phosphorylation and SOCS3 induction in m/h IL-10R1 chimera-infected cells. 1 x 106 macrophages were left uninfected or infected at an m.o.i. of 100 with Ad GFP, Ad m/h-IL-10R1, the Tyr-446 mutant (Y446F), Tyr-496 mutant (Y496F), the double Tyr mutant Tyr-446/496, and the C-terminal serine-rich region deletion (Ser-RD) mutants for 1 h. The virus was then removed and then left to express overnight. The next day cells were left unstimulated or stimulated with either human (10 ng/ml) or murine IL-10 (50 ng/ml) for 2 h. Cell lysates were subjected to Western blotting, and tyrosine-phosphorylated STAT3 was detected using a Tyr-705 phospho-specific antibody (a) and SOCS3 expression via SOCS3-specific antibodies (b). The blots were stripped and reprobed for beta-tubulin (c) to ensure equal loading. The figure is representative of at least three experiments performed. d, 1 x 105 macrophages were left uninfected or infected at an m.o.i. of 100 with Ad GFP adenovirus, m/h-IL-10RI chimera, or the m/h IL-10RI, the Tyr-446 mutant (Y446F), Tyr-496 mutant (Y496F), the double Tyr mutant Y446F/Y496F, the C-terminal serine-rich region deletion (Ser-RD) for 1 h, and the virus was removed and then left to express overnight. The next day cells were left unstimulated or stimulated with LPS (10 ng/ml) (solid black bars) with either human (10 ng/ml) (empty bars) or murine IL-10 (50 ng/ml) (gray bars). Cell supernatants were harvested after 18 h and TNF (d) and IL-6 (e) levels were determined by ELISA. The figure is representative of at least three experiments performed.

 
STAT3C Does Not Affect LPS-induced NF-{kappa}B or MAPK Activation but Does Induce Bcl-3 Expression—We were concerned that forced overexpression of STAT3C may have nonspecific effects on other luciferase-based reporter assays. To address this issue we investigated the effect of overexpression of STAT3C on an NF-{kappa}B luciferase reporter construct. This luciferase construct uses the NF-{kappa}B consensus site in a tandem repeat of four copies. Expression of STAT3C alone did not induce any activation of the NF-{kappa}B reporter gene. Also, STAT3C did not inhibit LPS-induced NF-{kappa}B activation (Fig. 4a). This is in agreement with our previous studies showing no effect of IL-10 on this NF-{kappa}B reporter gene system (27). In agreement with these data, STAT3C had no effect on LPS-induced I{kappa}B{alpha} degradation (Fig. 4b), although its ability to induce SOCS3 confirmed it was active in this assay. Another key signaling pathway induced by LPS is the activation of the mitogen-activated protein kinases (MAPK) (49, 50). Again, in agreement with our previous studies with IL-10 in primary human macrophages, STAT3C was unable to inhibit the LPS-induced phosphorylation of the MAP kinases p38, p42/44 ERK, or p54 JNK (Fig. 4c).

IL-10 induction of the NF-{kappa}B family member Bcl-3 has been proposed to play a key role in the regulation of TNF production, as demonstrated by the failure of macrophages from these Bcl-3-deficient mice to respond to IL-10, as IL-10 can no longer can suppress TNF production (33). We were therefore interested to determine whether expression of STAT3 alone could induce Bcl-3 expression. As shown in Fig. 4d, expression of STAT3C alone induced very high levels of expression of Bcl-3, which could not be further enhanced with co-stimulation with IL-10.


Figure 3
View larger version (36K):
[in this window]
[in a new window]

  		FIGURE 3.
Constitutively active STAT3 expression and activity in human macrophages. 5 x 105 cells were infected with Ad STAT3C with increasing m.o.i. (0–150) for 1 h; virus was then removed and left to express overnight. The next day cell lysates were subjected to Western blotting. a, STAT3C expression was determined by probing with an anti-FLAG antibody. The blot was stripped and reprobed with beta-tubulin to ensure equal loading. b, 1 x 105 macrophages were infected with increasing m.o.i. of Ad STAT3 luciferase (Lux) adenovirus for 1 h. The next day cells were stimulated ± IL-6 (10 ng/ml) (empty bars) or IL-10 (10 ng/ml) (gray bars) or macrophages were infected initially with STAT3 Lux (m.o.i. 40) for 1 h and then rested for 2 h prior to infection with increasing doses of Ad STAT3C (0–150) or an Ad GFP control (150 m.o.i.) for 1 h (c). The next day, cells were left unstimulated (gray bars) or stimulated IL-10 (ng/ml) (black bars) for 6 h. After 6 h, cells were lysed, and luciferase activity was measured by chemiluminescence. d, macrophages were infected with either Ad HA-STAT3 or Ad STAT3C-FLAG (m.o.i. 50). After overnight expression cells were stimulated with LPS (0–240 min) for 4 h. The levels of STAT3 phosphorylation were determined by probing with anti-phospho-Tyr-STAT3, followed by anti-HA, anti-FLAG, and anti-beta tubulin. e, Ad-STAT3C infected macrophages were stimulated ± LPS for 2 h. STAT3C was immunoprecipitated (IP) with anti-FLAG (M2) or an isotype control. The levels of STAT3 phosphorylation were determined by probing with anti-phospho-Tyr-STAT3, followed by anti-FLAG. f, macrophages were infected with either Ad GFP or Ad STAT3C-FLAG (m.o.i. 50). After overnight expression, the cells were stimulated with IL-10 for 4 h. Cell lysates were subjected to Western blotting, and expression was determined by probing with a SOCS3 antibodies. The blot was stripped and reprobed for STAT3 and beta-tubulin to ensure equal loading and STAT3C expression. These figures are representative of at least three experiments performed.

 
Overexpression of STAT3C Inhibits LPS-induced TNF and IL-6 Protein and mRNA Production—Given that STAT3C alone was able to induce Bcl-3, a key regulator of TNF production, we next investigated the ability of STAT3C to regulate pro-inflammatory cytokine production. Infection of macrophages with Ad STAT3C resulted in a dose-dependent inhibition of LPS-induced TNF, IL-6 (Fig. 5, a and b) and IL-8 (data not shown) production. The level of inhibition was similar to that seen with 10 ng/ml of IL-10, although at the higher m.o.i. of virus, TNF expression was totally ablated. In contrast, the control virus, Ad GFP, or wild type Ad STAT3 (data not shown) had no effect on cytokine production at the highest m.o.i. used. Adding IL-10 to Ad STAT3C-infected cells had some additive effect at the lowest m.o.i., but this was not found at higher m.o.i. where Ad STAT3C alone completely inhibited cytokine production. These studies were extended to examine cytokine production induced by ligands for TLRs other than TLR4, e.g. TLR2 (LTA, Pam3Cys, MALP2), TLR5 (flagellin), and TLR7/8 (R848) with very similar results (data not shown). Previously, we have shown that a STAT3 dominant negative construct had no effect upon LPS-induced IL-10 production (40). Consistent with these findings, expression of STAT3C did not affect LPS-induced IL-10 production (Fig. 5c). This also demonstrates that expression of STAT3C does not globally suppress all LPS-induced cytokine synthesis but specifically targets a subset of LPS-induced cytokines.

We have previously shown that IL-10 can suppress TNF mRNA when added simultaneously with LPS (40). As shown in Fig. 5, d and e, expression of the STAT3C inhibited LPS-induced TNF and IL-6 mRNA to comparable levels as observed with IL-10 treatment. STAT3C only affected the LPS-stimulated increase in IL-6/TNF production as basal levels of these mRNAs were unaffected by expression of STAT3C.

So far we have studied the effects of STAT3-dependent cytokine suppression in a model system of TLR-induced cytokine production in human macrophages. However, from an inflammatory disease perspective, a more clinically relevant system to study would be an ongoing inflammatory reaction. We have previously used rheumatoid synovium membrane extracted from patients undergoing joint replacement as a system to investigate the ongoing inflammation-driven cytokine production. We used the Ad STAT3C in this system to see if we could modify the spontaneous production of TNF and IL-6. Fig. 6 shows the data generated from four patients for TNF (TNF was not detectable in two patient samples) and six patients for IL-6. Addition of IL-10 strongly inhibited TNF production in keeping with our previous findings (51), whereas IL-10 only had only a mild inhibitory effect on IL-6 production. Infection with the Ad GFP had no effect upon the spontaneous production of either IL-6 or TNF. However, expression of the STAT3C significantly inhibited TNF production, although not to the same degree as IL-10. This may be a reflection of the time lag between infection of the virus and expression of the STAT3C protein; there will be a window of time where the cells are releasing TNF, prior to expression of the STAT3C protein. Similarly, Ad STAT3C infection only caused a mild but still significant inhibition of IL-6 production.


Figure 4
View larger version (35K):
[in this window]
[in a new window]

  		FIGURE 4.
Constitutively active STAT3 does not modify NF-{kappa}B and MAPK activity but does induced BCL3 expression. a, 1 x 105 macrophages were infected with Ad NF-{kappa}B-reporter virus (m.o.i. of 50) prior to infection with either Ad GFP or Ad STAT3C (m.o.i. of 50). The next day cells were stimulated ±LPS (10 ng/ml) for 4 h; the cells were then lysed, and luciferase activity was measured by chemiluminescence. uns indicates unstimulated. b, cells were infected with either Ad GFP or Ad STAT3C (m.o.i. 50). The next day the cells were stimulated with LPS (10 ng/ml) over a 60-min time course. Cell lysates were subjected to Western blotting and probed with anti-I{kappa}B or anti-SOCS3 antibodies. STAT3C expression was determined by probing with an anti-STAT3 antibody. c, cell lysates were subjected to Western blotting and probed with phospho-specific (P) anti-JNK, p42/p44 MAPK, and p38 MAPK. d, 2 x 106 cells were infected with either Ad GFP or Ad STAT3C (m.o.i. 50) for 1 h. After 18 h, cells were stimulated with IL-10 for 8 h. Cell lysates were subjected to Western blotting, and Bcl-3 expression was determined by probing with an anti-Bcl3 antibody. The blot was stripped and reprobed for STAT3 and beta-tubulin to ensure equal loading and STAT3C expression. These experiments are representative of three independent donors.

 
STAT3 is present and is activated in many cell types by various stimuli that are not associated with anti-inflammatory activities. We were therefore interested to determine whether the effects of STAT3C were specific to cells of the myeloid lineages or whether STAT3C could display these profound cytokine-suppressive qualities in all cell types. To address this issue we cultured RA synovial cells over multiple passages (routinely 4) until they consisted of only synovial fibroblasts. We have shown previously (52) that these cells respond to LPS and produce pro-inflammatory cytokines. We infected these cells with either Ad GFP or Ad STATC, and we assessed their ability to respond to LPS-induced IL-6 production (as they do not produce significant quantities of TNF). In contrast to the inhibitory activities displayed in macrophages and RA synovial cells, STAT3C actually significantly enhanced production of both spontaneous and LPS-induced IL-6 production (Fig. 6c), suggesting that the cytokine suppressive activities of this molecule may indeed be limited to cells of the myeloid lineage. This was further supported by similar experiments performed in IL-1-stimulated HeLa cells. Again, expression of STAT3C enhanced IL-6 production (Fig. 6d) and IL-8 (data not shown).


   DISCUSSION
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
REFERENCES
 
Despite being recognized as a powerful anti-inflammatory cytokine for well over a decade, the mechanism involved in mediating the activity of IL-10 has remained largely unresolved. The requirement for STAT3 is possibly the only parameter where there is general agreement. However, this has led to further questions. As STAT3 is activated by many cytokines, is another pathway, in addition to STAT3, required to specifically translate the anti-inflammatory activity of IL-10? This study confirms, in human macrophages, the absolute requirement of the STAT3-docking sites within the cytoplasmic domain of the human IL-10R1 chain in mediating STAT3 activation, SOCS3 induction, and the suppression of cytokine synthesis. Furthermore, these data are the first to show that STAT3 is not only necessary but also appears to be sufficient to transmit the cytokine suppressive activities of IL-10 and that no other signal from the IL-10 receptor is required, in human macrophages, for this particular function.

The cytoplasmic tail of murine IL-10RI contains tyrosine residues at positions 374, 396, 427, and 477. Only two of these, Tyr-446 and Tyr-496, are conserved in the human receptor and both are within the STAT3-binding YXXQ motif (16). It had been shown previously in murine macrophage cell lines that mutation of Tyr-427/446 and Tyr-477/496 resulted in a loss of IL-10 signaling as measured by a failure to induce STAT3 and the inhibitory effects on macrophage function (38, 53). However, the study of O'Farrell et al. (53) in the J774 murine macrophage cell line went on to show that STAT3 was not required for the inhibition of macrophage activation, i.e. cytokine production and CD86 expression. In contrast, Riley et al. (38) working in RAW264.7 cells concluded that an additional signal derived from a serine-rich region near the C terminus was required in addition to STAT3 to provide the anti-inflammatory signal. The precise nature of this signal has never been elucidated. Moreover, the importance of STAT3 has been supported by studies in primary murine STAT3–/– macrophages that showed impaired IL-10 function (37), suggesting that the data of O'Farrell et al. (53) could be unique to the J774 cell line. However, the lack of STAT3 does not preclude that other additional signals are required to mediate the anti-inflammatory activity of IL-10. A second signal, as proposed by Riley et al. (38), could have explained why STAT3, a signal common to numerous cytokines, appears to be anti-inflammatory only in the context of IL-10. However, this study shows that activated STAT3 alone can mimic many of the anti-inflammatory activities of IL-10, i.e. inhibition of LPS-induced TNF and IL-6 mRNA and protein production and the induction of Bcl-3. Given the data, we are only able to conclude that the difference between this study and that of Riley et al. (38) could be down to differences in the cell system/species used or the m/h IL-10R1 chimera versus the interferon {gamma}/IL-10R used (38). Specifically, in our system the m/hIL-10R1 would be able to recruit the endogenous IL-10R2, whereas the chimeric receptors used by Riley et al. (38) would recruit the IFNGR2 chain. With respect to the difference between species, it is worth noting that the forced expression of STAT3C in murine dendritic cells was unable to inhibit TNF, contrary to our findings. However, this construct was able to inhibit IL-12 production (39). These data would support the requirement for an additional signal, other than STAT3, that is required to mediate the cytokine-suppressive effects of IL-10 in murine cells, but as our data show, this does not appear to be the case in human cells.


Figure 5
View larger version (22K):
[in this window]
[in a new window]

  		FIGURE 5.
Constitutively active STAT3 is sufficient for cytokine suppressive activity. 1 x 105 macrophages were infected with Ad STAT3C m.o.i. of 50 or an Ad GFP control (50 m.o.i.) for 1 h; virus was removed and then left to express overnight. The next day, cells were left unstimulated (open bars) or stimulated with LPS (10 ng/ml) (solid bars) ± hIL-10 (10 ng/ml) (empty bars). After 18 h supernatants were harvested, and TNF (a) IL-6 (b) and IL-10 (c) levels were determined by ELISA. Alternatively cells were stimulated for 2 h with LPS (10 ng/ml) (±) IL-10 (10 ng/ml); RNA was extracted, and mRNA analysis was performed using Taqman PCR to detect TNF (d) or IL-6 (e) mRNA. These experiments are representative of three independent donors.

 
It is worth noting that STAT3C could not mimic all the activities of IL-10, as IL-10-induced expression of I{kappa}B{zeta} and B-ATF2 was not reproduced by STAT3C, and its overexpression resulted in decreased STAT1 expression (data not shown), which has been shown previously by others (54). STAT3C is predominantly localized within the nucleus, which is in contrast to the transient nature of IL-10-induced nuclear accumulation of STAT3. This persistent nuclear accumulation may well account for differences between IL-10-induced STAT3 activation and STAT3C action. STAT3C may be acting as a transrepressor by sequestering away co-factors/transcription factors from the promoters as these genes. For example, we observe STAT3C binding to the p65 subunit of the transcription factor NF-{kappa}B.3 This binding may sterically hinder association of the p65 with other cofactors required for the full transcription activity and thus inhibit transcription of NF-{kappa}B-driven genes such as TNF and IL-6.

It has been shown recently that STAT3C requires tyrosine phosphorylation for maximal DNA binding affinity (47, 48). In unstimulated macrophages, we observed that STAT3C was only minimally tyrosine-phosphorylated, but this phosphorylation could be substantially enhanced by the addition of LPS. This basal level of tyrosine phosphorylation would appear to be sufficient to drive the transcription of Bcl-3; however, in the case of SOCS3, the increased level of tyrosine phosphorylation may significantly enhance the ability of STAT3C to give the optimal transcriptional response. Alternatively, as IL-10 induces other signaling pathways, distinct from the JAK/STAT3 pathway, these may contribute to the regulation of SOCS3. One of these is likely to be PI3K, and we have shown previously that IL-10-induced HO-1 expression requires both the STAT3 and PI3K pathways (55). Supporting this view, we have observed that inhibition of PI3K by either LY294002 or wortmannin partially inhibits IL-10-induced SOCS3 expression3; however, this kinase is not required for IL-10 suppression of TNF and IL-6 production in human cells (56).


Figure 6
View larger version (20K):
[in this window]
[in a new window]

  		FIGURE 6.
Constitutively active STAT3 suppresses TNF and IL-6 production in RA mononuclear cells but enhances IL-6 production in nonmyeloid cells. 1 x 105 RA synovial membrane cells were left uninfected or were infected with Ad GFP or Ad STAT3C and treated ± IL-10 (10 ng/ml). Cells were cultured for another 2 days. Supernatants were collected and examined for the presence of TNF (a) or IL-6 (b) by ELISA. Values are the mean ± S.D. of cytokine production in triplicate cultures, from six unrelated patients. For statistical analysis of these parametric data, Student's t test was used to compare Ad GFP control cells with Ad STAT3C. NS = not significant; uns = unstimulated. * = p < 0.05; ** = p < 0.01; *** = p < 0.001. 5 x 103 RA synovial fibroblasts (passage 4) (c) or HeLa cells (d) were infected with either Ad GFP or Ad STAT3C (m.o.i. of 150–300 SF or 10–50 in HeLa cells) for 2 h. The next day, cells were stimulated ± LPS (10 ng/ml) or IL-1 (10 ng/ml), and supernatants were collected after 18 h and IL-6 levels determined by ELISA.

 
Given that many other cytokines activate STAT3, it might seem unlikely that this signal alone would be sufficient to mediate the anti-inflammatory response of IL-10. The answer to this may lie in quantitative rather than qualitative aspects of signaling. IL-10 is quite unique in its ability to induce a sustained level of STAT3 phosphorylation. Although other cytokines induce STAT3 phosphorylation, this activation is only transient. IL-6 is a potent activator of STAT3 in macrophages but only induces a burst of activation, lasting only a few hours, which is then rapidly deactivated by mechanisms such as SOCS3 induction. In SOCS3-deficient mice, a sustained activation of STAT3 by IL-6 was observed, and the cytokine displayed anti-inflammatory properties (57, 58). This may suggest that IL-10 is such a potent anti-inflammatory cytokine by virtue of its ability to deliver a sustained STAT3 activation, because SOCS3 is unable to deactivate the IL-10R system (57), which of course would be more than adequately mimicked by the STAT3C construct. However, we cannot rule out the possibility that the enhanced level of tyrosine phosphorylation on STAT3C we observed following LPS stimulation is responsible for mediating the effect of STAT3C on TNF and IL-6 production. As this phosphorylation is only evident after 60 min, it may suggest that it is not direct and rather is mediated from another LPS-induced cytokine. However, it does not detract from the central observation that STAT3 is mediating these cytokine-suppressive effects.

Another possibility is that the cellular context of STAT3 is important to its generation of the anti-inflammatory response. It is worth noting that another member of the IL-10-interferon family, IL-22, has been considered to be pro-inflammatory in hepatocytes. This cytokine also utilizes the IL-10R2 chain and is a strong activator of STAT3, but it actually induces the expression of pro-inflammatory mediators (59, 60). Our studies in synovial fibroblasts and HeLa cells support such a possibility, suggesting that the cellular environment is an important key to the fate of STAT3 activation.

Our studies have naturally led to the question as to how STAT3 might mediate the anti-inflammatory effects of IL-10. Much controversy exists within the IL-10 field, and various studies have proposed that IL-10 inhibits NF-{kappa}B (26, 30) or, alternatively, p38 MAPK activation (29, 61). However, consistent with previous studies in human macrophages, we found no effect of STAT3C on either pathway (27). There is much evidence to suggest that STAT3 is required to induce the expression of intermediate genes. HO-1 and Bcl-3 have both been proposed for this role. As mentioned, HO-1 is not induced by STAT3 alone but requires the PI3K pathway (55), but we were able to show that Bcl-3 is induced by STAT3C alone. Therefore, our data are consistent with a signaling pathway whereby IL-10 induces Bcl-3 via STAT3 to block TNF expression. However, it must be noted that macrophages deficient in Bcl3 are still responsive to IL-10 suppression of IL-6 (33), suggesting that IL-10 utilizes multiple mechanisms, distal of STAT3, to suppress cytokine synthesis. To further elucidate the role of STAT3, we are currently profiling the array of genes driven by STAT3C expression to address this pivotal question.

In summary, this study has investigated a key aspect of the molecular mechanism by which the anti-inflammatory activity of IL-10 is mediated. Using the relatively homologous system of an m/h IL-10RI chimera expressed in human primary macrophages, this study showed that loss of the tyrosines 446/496 resulted in the loss of STAT3 activity, which correlated with loss of anti-inflammatory signaling. The study goes on to show that not only is STAT3 necessary but it is sufficient to replicate the cytokine suppressive activities of IL-10 in human macrophages. In addition, the study goes on to define the cellular environment as a critical factor in determining whether STAT3 can be considered to be an anti-inflammatory mediator.


   FOOTNOTES
 
* This work was supported by the Biotechnology and Biological Sciences Research Council, Wellcome Trust and the British Heart Foundation. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Back

1 To whom correspondence should be addressed. Tel.: 44-208-383-4429; Fax: 44-208-383-4499; E-mail: b.foxwell{at}imperial.ac.uk.

2 The abbreviations used are: IL, interleukin; STAT3, signal transducer and activation of transcription; TNF, tumor necrosis factor; LPS, lipopolysaccharide; ELISA, enzyme-linked immunosorbent assay; GFP, green fluorescent protein; MAPK, mitogen-activated protein kinase; PBS, phosphate-buffered saline; FACS, fluorescence-activated cell sorter; m/h, murine/human; IFN, interferon; m.o.i., multiplicity of infection; ERK, extracellular signal-regulated kinase; JNK, c-Jun N-terminal kinase; R, receptor; HA, hemagglutinin; PI3K, phosphatidylinositol 3-kinase; Ad, adenovirus; RA, rheumatoid arthritis. Back

3 L. M. Williams, U. Sarma, K. Willets, T. Smallie, F. Brennan, and B. M. J. Foxwell, unpublished observations. Back


   ACKNOWLEDGMENTS
 
We thank Dr Michitaka Ozaki and Dr. Paul McCray for the use of the STAT3C and NF-{kappa}B adenoviruses. We also thank Drs. Udalova, Page, Gregory, and Horwood for critical reading of this manuscript.



   REFERENCES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Kuhn, R., Loher, J., Rennick, D., Rajewsky, K., and Muller, W. (1993) Cell 75, 263–274[CrossRef][Medline] [Order article via Infotrieve]
  2. Gerard, C., Bruyns, C., Marchant, A., Abramowicz, D., Vandenabeele, P., Delvaux, A., Fiers, W., Goldman, M., and Velu, T. (1993) J. Exp. Med. 177, 547–550[Abstract/Free Full Text]
  3. Walmsley, M., Katsikis, P. D., Abney, E., Parry, S., Williams, R. O., Maini, R. N., and Feldmann, M. (1996) Arthritis Rheum. 39, 495–503[Medline] [Order article via Infotrieve]
  4. Kolb, H., Worz-Pagenstert, U., Kleemann, R., Rothe, H., Rowsell, P., Rastegar, S., and Scott, F. W. (1997) Autoimmunity 26, 1–6[Medline] [Order article via Infotrieve]
  5. Cua, D. J., Coffman, R. L., and Stohlman, S. A. (1996) J. Immunol. 157, 2830–2836[Abstract]
  6. Cua, D. J., Groux, H., Hinton, D. R., Stohlman, S. A., and Coffman, R. L. (1999) J. Exp. Med. 189, 1005–1010[Abstract/Free Full Text]
  7. He, T. C., Zhou, S., da Costa, L. T., Yu, J., Kinzler, K. W., and Vogelstein, B. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 2509–2514[Abstract/Free Full Text]
  8. Fedorak, R. N., Gangl, A., Elson, C. O., Rutgeerts, P., Schreiber, S., Wild, G., Hanauer, S. B., Kilian, A., Cohard, M., LeBeaut, A., and Feagan, B. (2000) Gastroenterology 119, 1473–1482[CrossRef][Medline] [Order article via Infotrieve]
  9. Keystone, E., Wherry, J., and Grint, P. (1998) Rheum Dis. Clin. North Am. 24, 629–639[CrossRef][Medline] [Order article via Infotrieve]
  10. Moore, K. W., de Waal Malefyt, R., Coffman, R. L., and O'Garra, A. (2001) Annu. Rev. Immunol. 19, 683–765[CrossRef][Medline] [Order article via Infotrieve]
  11. Buelens, C., Willems, F., Delvaux, A., Pierard, G., Delville, J. P., Velu, T., and Goldman, M. (1995) Eur. J. Immunol. 25, 2668–2672[Medline] [Order article via Infotrieve]
  12. Chang, C. H., Furue, M., and Tamaki, K. (1995) Eur. J. Immunol. 25, 394–398[Medline] [Order article via Infotrieve]
  13. Ding, L., Linsley, P. S., Huang, L. Y., Germain, R. N., and Shevach, E. M. (1993) J. Immunol. 151, 1224–1234[Abstract]
  14. Joyce, D. A., Gibbons, D. P., Green, P., Steer, J. H., Feldmann, M., and Brennan, F. M. (1994) Eur. J. Immunol. 24, 2699–2705[Medline] [Order article via Infotrieve]
  15. de Waal Malefyt, R., Yssel, H., and de Vries, J. E. (1993) J. Immunol. 150, 4754–4765[Abstract]
  16. Liu, Y., Wei, S. H., Ho, A. S., de Waal Malefyt, R., and Moore, K. W. (1994) J. Immunol. 152, 1821–1829[Abstract]
  17. Tan, J. C., Braun, S., Rong, H., DiGiacomo, R., Dolphin, E., Baldwin, S., Narula, S. K., Zavodny, P. J., and Chou, C. C. (1995) J. Biol. Chem. 270, 12906–12911[Abstract/Free Full Text]
  18. Lutfalla, G., Gardiner, K., Proudhon, D., Vielh, E., and Uze, G. (1992) J. Biol. Chem. 267, 2802–2809[Abstract/Free Full Text]
  19. Kotenko, S. V., Krause, C. D., Izotova, L. S., Pollack, B. P., Wu, W., and Pestka, S. (1997) EMBO J. 16, 5894–5903[CrossRef][Medline] [Order article via Infotrieve]
  20. Finbloom, D. S., and Winestock, K. D. (1995) J. Immunol. 155, 1079–1090[Abstract]
  21. Larner, A., David, M., Feldman, G. M., Igarashi, K., Hackett, R. H., Webb, D. S., Sweizer, S. M., Petricoin, E. F., and Finbloom, D. S. (1993) Science 261, 1730–1733[Abstract/Free Full Text]
  22. Ho, A. S., Wei, S. H., Mui, A. L., Miyajima, A., and Moore, K. W. (1995) Mol. Cell. Biol. 15, 5043–5053[Abstract]
  23. Weber-Nordt, R. M., Egen, C., Wehinger, J., Ludwig, W., Gouilleux-Gruart, V., Mertelsmann, R., and Finke, J. (1996) Blood 88, 809–816[Abstract/Free Full Text]
  24. Weber-Nordt, R. M., Riley, J. K., Greenlund, A. C., Moore, K. W., Darnell, J. E., and Schreiber, R. D. (1996) J. Biol. Chem. 271, 27954–27961[Abstract/Free Full Text]
  25. Clarke, C. J., Hales, A., Hunt, A., and Foxwell, B. M. (1998) Eur. J. Immunol. 28, 1719–1726[CrossRef][Medline] [Order article via Infotrieve]
  26. Wang, P., Wu, P., Siegel, M. I., Egan, R. W., and Billah, M. M. (1995) J. Biol. Chem. 270, 9558–9563[Abstract/Free Full Text]
  27. Denys, A., Udalova, I. A., Smith, C., Williams, L. M., Campbell, J., Andrews, C., Kwaitkowski, D., and Foxwell, B. M. (2002) J. Immunol. 168, 4837–4845[Abstract/Free Full Text]
  28. Keffer, J., Probert, L., Cazlaris, H., Georgopoulos, S., Kaslaris, E., Kioussis, D., and Kollias, G. (1991) EMBO J. 10, 4025–4031[Medline] [Order article via Infotrieve]
  29. Kontoyiannis, D., Kotlyarov, A., Carballo, E., Alexopoulou, L., Blackshear, P. J., Gaestel, M., Davis, R., Flavell, R., and Kollias, G. (2001) EMBO J. 20, 3760–3770[CrossRef][Medline] [Order article via Infotrieve]
  30. Schottelius, A. J., Mayo, M. W., Sartor, R. B., and Baldwin, A. S., Jr. (1999) J. Biol. Chem. 274, 31868–31874[Abstract/Free Full Text]
  31. Bogdan, C., Paik, J., Vodovotz, Y., and Nathan C. (1992) J. Biol. Chem. 267, 23301[Abstract/Free Full Text]
  32. Aste-Amezaga, M., Ma, X., Sartori, A., and Trinchieri, G. (1998) J. Immunol. 160, 5936–5944[Abstract/Free Full Text]
  33. Kuwata, H., Watanabe, Y., Miyoshi, H., Yamamoto, M., Kaisho, T., Takeda, K., and Akira, S. (2003) Blood 102, 4123–4129[Abstract/Free Full Text]
  34. Biswas, R., Datta, S., Gupta, J. D., Novotny, M., Tebo, J., and Hamilton, T. A. (2003) J. Immunol. 170, 6202–6208[Abstract/Free Full Text]
  35. Murray, P. J. (2005) Proc. Natl. Acad. Sci. U. S. A. 102, 8686–8691[Abstract/Free Full Text]
  36. Rodig, S. J., Meraz, M. A., White, J. M., Lampe, P. A., Riley, J. K., Arthur, C. D., King, K. L., Sheehan, K. C., Yin, L., Pennica, D., Johnson, E. M., Jr., and Schreiber, R. D. (1998) Cell 93, 373–383[CrossRef][Medline] [Order article via Infotrieve]
  37. Takeda, K., Clausen, B. E., Kaisho, T., Tsujimura, T., Terada, N., Forster, I., and Akira, S. (1999) Immunity 10, 39–49[CrossRef][Medline] [Order article via Infotrieve]
  38. Riley, J. K., Takeda, K., Akira, S., and Schreiber, R. D. (1999) J. Biol. Chem. 274, 16513–16521[Abstract/Free Full Text]
  39. Hoentjen, F., Sartor, R. B., Ozaki, M., and Jobin, C. (2005) Blood 105, 689–696[Abstract/Free Full Text]
  40. Williams, L., Bradley, L., Smith, A., and Foxwell, B. (2004) J. Immunol. 172, 567–576[Abstract/Free Full Text]
  41. Foxwell, B., Browne, K., Bondeson, J., Clarke, C., de Martin, R., Brennan, F., and Feldmann, M. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 8211–8215[Abstract/Free Full Text]
  42. Besser, D., Bromberg, J. F., Darnell, J. E., Jr., and Hanafusa, H. (1999) Mol. Cell. Biol. 19, 1401–1409[Abstract/Free Full Text]
  43. Haga, S., Terui, K., Zhang, H. Q., Enosawa, S., Ogawa, W., Inoue, H., Okuyama, T., Takeda, K., Akira, S., Ogino, T., Irani, K., and Ozaki, M. (2003) J. Clin. Investig. 112, 989–998[CrossRef][Medline] [Order article via Infotrieve]
  44. Sanlioglu, S., Williams, C. M., Samavati, L., Butler, N. S., Wang, G., McCray, P. B., Jr., Ritchie, T. C., Hunninghake, G. W., Zandi, E., and Engelhardt, J. F. (2001) J. Biol. Chem. 276, 30188–30198[Abstract/Free Full Text]
  45. Stahl, N., Farruggella, T. J., Boulton, T. G., Zhong, Z., Darnell, J. E., Jr., and Yancopoulos, G. D. (1995) Science 267, 1349–1353[Abstract/Free Full Text]
  46. Bromberg, J. F., Wrzeszczynska, M. H., Devgan, G., Zhao, Y., Pestell, R. G., Albanese, C., and Darnell, J. E., Jr. (1999) Cell 98, 295–303[CrossRef][Medline] [Order article via Infotrieve]
  47. Liddle, F. J., Alvarez, J. V., Poli, V., and Frank, D. A. (2006) Biochemistry 45, 5599–5605[CrossRef][Medline] [Order article via Infotrieve]
  48. Li, L., and Shaw, P. E. (2006) J. Biol. Chem. 281, 33172–33181[Abstract/Free Full Text]
  49. Foey, A. D., Parry, S. L., Williams, L. M., Feldmann, M., Foxwell, B. M. J., and Brennan, F. M. (1998) J. Immunol. 160, 920–928[Abstract/Free Full Text]
  50. Lee, J. C., Laydon, J. T., McDonnell, P. C., Gallagher, T. F., Kumar, S., Green, D., McNulty, D., Blumenthal, M. J., Heys, J. R., Landvatter, S. W., Strickler, J. E., McLaughlin, M. M., Siemens, I. R., Fisher, S. M., Livi, G. P., White, J. R., Adams, J. L., and Young, P. R. (1994) Nature 372, 739–746[CrossRef][Medline] [Order article via Infotrieve]
  51. Katsikis, P. D., Chu, C.-Q., Brennan, F. M., Maini, R. N., and Feldmann, M. (1994) J. Exp. Med. 179, 1517–1527[Abstract/Free Full Text]
  52. Andreakos, E., Smith, C., Kiriakidis, S., Monaco, C., de Martin, R., Brennan, F. M., Paleolog, E., Feldmann, M., and Foxwell, B. M. (2003) Arthritis Rheum. 48, 1901–1912[CrossRef][Medline] [Order article via Infotrieve]
  53. O'Farrell, M., Liu Y., Moore, K. W., and Mui, A. L. (1998) EMBO J. 17, 1006–1018[CrossRef][Medline] [Order article via Infotrieve]
  54. Dauer, D. J., Ferraro, B., Song, L., Yu, B., Mora, L., Buettner, R., Enkemann, S., Jove, R., and Haura, E. B. (2005) Oncogene 24, 3397–3408[CrossRef][Medline] [Order article via Infotrieve]
  55. Ricchetti, G., Williams, L. M., and Fowell, B. M. J. (2004) J. Leukocyte Biol. 76, 719–726[Abstract/Free Full Text]
  56. Crawley, J. B., Williams, L. M., Mander, T., Brennan, F. M., and Foxwell, B. M. (1996) J. Biol. Chem. 271, 16357–16362[Abstract/Free Full Text]
  57. Lang, R., Pauleau, A. L., Parganas, E., Takahashi, Y., Mages, J., Ihle, J. N., Rutschman, R., and Murray, P. J. (2003) Nat. Immun. 4, 546–550
  58. Yasukawa, H., Ohishi, M., Mori, H., Murakami, M., Chinen, T., Aki, D., Hanada, T., Takeda, K., Akira, S., Hoshijima, M., Hirano, T., Chien, K. R., and Yoshimura, A. (2003) Nat. Immun. 4, 551–556
  59. Renauld, J. C. (2003) Nat. Rev. Immunol. 3, 667–676[CrossRef][Medline] [Order article via Infotrieve]
  60. Pestka, S., Krause, C. D., Sarkar, D., Walter, M. R., Shi, Y., and Fisher, P. B. (2004) Annu. Rev. Immunol. 22, 929–979[CrossRef][Medline] [Order article via Infotrieve]
  61. Rajasingh, J., Bord, E., Luedemann, C., Asai, J., Hamada, H., Thorne, T., Qin, G., Goukassian, D., Zhu, Y., Losordo, D. W., and Kishore, R. (2006) FASEB J. 20, 2112–2114[Abstract/Free Full Text]

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 J. Immunol.Home page
B. Schaljo, F. Kratochvill, N. Gratz, I. Sadzak, I. Sauer, M. Hammer, C. Vogl, B. Strobl, M. Muller, P. J. Blackshear, et al.
Tristetraprolin Is Required for Full Anti-Inflammatory Response of Murine Macrophages to IL-10
J. Immunol., July 15, 2009; 183(2): 1197 - 1206.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
N. R. Patel, K. Swan, X. Li, S. D. Tachado, and H. Koziel
Impaired M. tuberculosis-mediated apoptosis in alveolar macrophages from HIV+ persons: potential role of IL-10 and BCL-3
J. Leukoc. Biol., July 1, 2009; 86(1): 53 - 60.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
E. Beurel and R. S. Jope
Differential Regulation of STAT Family Members by Glycogen Synthase Kinase-3
J. Biol. Chem., August 8, 2008; 283(32): 21934 - 21944.
[Abstract] [Full Text] [PDF]

Home page
 Int ImmunolHome page
A. Tripathi and A. Sodhi
Prolactin-induced production of cytokines in macrophages in vitro involves JAK/STAT and JNK MAPK pathways
Int. Immunol., March 1, 2008; 20(3): 327 - 336.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
S. Kennedy Norton, B. Barnstein, J. Brenzovich, D. P. Bailey, M. Kashyap, K. Speiran, J. Ford, D. Conrad, S. Watowich, M. R. Moralle, et al.
IL-10 Suppresses Mast Cell IgE Receptor Expression and Signaling In Vitro and In Vivo
J. Immunol., March 1, 2008; 180(5): 2848 - 2854.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
K. C. El Kasmi, A. M. Smith, L. Williams, G. Neale, A. Panopolous, S. S. Watowich, H. Hacker, B. M. J. Foxwell, and P. J. Murray
Cutting Edge: A Transcriptional Repressor and Corepressor Induced by the STAT3-Regulated Anti-Inflammatory Signaling Pathway
J. Immunol., December 1, 2007; 179(11): 7215 - 7219.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
K. J. Staples, T. Smallie, L. M. Williams, A. Foey, B. Burke, B. M. J. Foxwell, and L. Ziegler-Heitbrock
IL-10 Induces IL-10 in Primary Human Monocyte-Derived Macrophages via the Transcription Factor Stat3
J. Immunol., April 15, 2007; 178(8): 4779 - 4785.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
282/10/6965    most recent
M609101200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Williams, L. M.
Right arrow Articles by Foxwell, B. M. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Williams, L. M.
Right arrow Articles by Foxwell, B. M. J.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2007 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement